These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 30460579)
1. Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative de Heer EC; Brouwers AH; Boellaard R; Sluiter WJ; Diercks GFH; Hospers GAP; de Vries EGE; Jalving M EJNMMI Res; 2018 Nov; 8(1):101. PubMed ID: 30460579 [TBL] [Abstract][Full Text] [Related]
2. Radiomics analysis of pre-treatment [ van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460 [TBL] [Abstract][Full Text] [Related]
3. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients. Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759 [TBL] [Abstract][Full Text] [Related]
5. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849 [TBL] [Abstract][Full Text] [Related]
6. Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer. Woff E; Hendlisz A; Ameye L; Garcia C; Kamoun T; Guiot T; Paesmans M; Flamen P J Nucl Med; 2019 Feb; 60(2):178-184. PubMed ID: 29959212 [TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
8. (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. Lovinfosse P; Koopmansch B; Lambert F; Jodogne S; Kustermans G; Hatt M; Visvikis D; Seidel L; Polus M; Albert A; Delvenne P; Hustinx R Br J Radiol; 2016 Jul; 89(1063):20160212. PubMed ID: 27146067 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Kim JW; Oh JS; Roh JL; Kim JS; Choi SH; Nam SY; Kim SY Eur J Nucl Med Mol Imaging; 2015 Aug; 42(9):1353-61. PubMed ID: 26067088 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
11. Assessing immune organs on Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374 [TBL] [Abstract][Full Text] [Related]
12. Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma. van Sluis J; de Heer EC; Boellaard M; Jalving M; Brouwers AH; Boellaard R Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1498-1510. PubMed ID: 33099667 [TBL] [Abstract][Full Text] [Related]
13. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Kudura K; Dimitriou F; Basler L; Förster R; Mihic-Probst D; Kutzker T; Dummer R; Mangana J; Burger IA; Kreissl MC Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359730 [TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma]. Wu LL; Liang JH; Wang L; Xu W; Ding CY Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850 [No Abstract] [Full Text] [Related]
15. (18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. Carlino MS; Saunders CA; Haydu LE; Menzies AM; Martin Curtis C; Lebowitz PF; Kefford RF; Long GV Eur J Cancer; 2013 Jan; 49(2):395-402. PubMed ID: 22981500 [TBL] [Abstract][Full Text] [Related]
17. Lymph node standardized uptake values at pre-treatment Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776 [TBL] [Abstract][Full Text] [Related]
18. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020 [TBL] [Abstract][Full Text] [Related]
19. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression? van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329 [TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160 [No Abstract] [Full Text] [Related] [Next] [New Search]